BTIG Maintains Buy on GeneDx Hldgs, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Buy rating on GeneDx Holdings (NASDAQ:WGS) and raises the price target from $35 to $45.
July 31, 2024 | 6:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Mark Massaro has maintained a Buy rating on GeneDx Holdings and increased the price target from $35 to $45.
The increase in the price target from $35 to $45 by a reputable analyst like Mark Massaro from BTIG is a positive signal for investors. This suggests confidence in the company's future performance, likely leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100